Drugs / MEDI5884
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03001297 | Jan 2017 → Aug 2018 | — | MedImmune LLC | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03351738 | Dec 2017 → Nov 2018 | coronary artery disorder | MedImmune LLC | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MEDI5884 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03001297 ↗ |
| Action | Inhibit | “CONCLUSIONS: Inhibition of EL by MEDI5884 increases the quantity and quality of functional HDL in patients with stable coronary artery disease on high-intensity statin therapy...” PMID 34706556 ↗ Oct 2021 |
| Modality | Monoclonal antibody | “MEDI5884 is a selective, humanized, monoclonal, EL-neutralizing antibody.” PMID 34706556 ↗ Oct 2021 |
| Route | Subcutaneous | “single ascending subcutaneous doses of MEDI5884” NCT03001297 ↗ |